Guardion Health Sciences (GHSI) 10-K 30 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 17, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	1,642,375
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		25,146,438

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash	$ 62,520	$ 13,850
Accounts receivable	1,673	1,136
Inventories	43,999	30,563
Current portion of deposits and prepaid expenses	29,363	18,950
Total current assets	137,555	64,499
Deposits and prepaid expenses, less current portion	10,470	10,470
Property and equipment, net	114,020	170,795
Total assets	262,045	245,764
Current liabilities
Accounts payable and accrued liabilities	356,467	271,863
Accrued expenses and deferred lease costs	88,290	143,077
Due to related parties	91,483	286,844
Current portion of convertible notes payable	44,323	41,315
Current portion of promissory notes payable, net of debt discount of $0 and $36,018, respectively	10,251	64,407
Current portion of promissory notes payable related party, net of debt discount of $0 and $54,639, respectively	16,805	149,233
Total current liabilities	607,619	956,739
Convertible notes payable	0	516,575
Total liabilities	607,619	1,473,314
Commitments and contingencies
Members' and Stockholders' Deficiency
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 1,705,154 shares issued and outstanding at December 31, 2016	1,705	0
Common stock, $0.001 par value; 90,000,000 shares authorized; 25,046,438 and 21,911,396 shares issued and outstanding at December 31, 2016 and December 31, 2015	25,046	21,911
Additional paid-in capital	20,277,882	12,857,320
Accumulated deficit	(20,650,207)	(14,106,781)
Total members' and stockholders' deficiency	(345,574)	(1,227,550)
Total liabilities, and members’ and stockholders’ deficiency	$ 262,045	$ 245,764

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Preferred Stock, Shares Authorized	10,000,000
Preferred Stock, Shares Issued	1,705,154
Preferred Stock, Shares Outstanding	1,705,154
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	25,046,438	21,911,396
Common Stock, Shares, Outstanding	25,046,438	21,911,396
Promissory Notes Payable [Member]
Debt Discount Current	$ 0	$ 36,018
Promissory Notes Payable Related Party [Member]
Debt Discount Current	$ 0	$ 54,639

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 141,029	$ 112,811
Cost of goods sold	75,702	50,072
Gross profit	65,327	62,739
Operating expenses
Research and development	64,026	401,909
Sales and marketing	389,111	180,133
General and administrative	3,308,144	5,610,830
Loss on settlement of promissory notes and accounts payable	249,739	258,606
Total operating expenses	4,011,020	6,451,478
Loss from operations	(3,945,693)	(6,388,739)
Other expenses:
Interest expense and financing costs	1,104,557	752,948
Change in fair value of note	698,147	0
Cost to induce conversion of notes payable	0	1,699,609
Total other expenses	1,802,704	2,452,557
Net loss	(5,748,397)	(8,841,296)
Adjustments related to Series A 8% convertible preferred stock:
Accretion of deemed dividend	(760,011)	0
Dividend declared	(35,018)	0
Net loss attributable to common shareholders	$ (6,543,426)	$ (8,841,296)
Net loss per common share - basic and diluted	$ (0.30)	$ (0.54)
Weighted average common shares outstanding - basic and diluted	21,800,719	16,391,665

Statements of Members_ and Stoc

Statements of Members’ and Stockholders' Deficit - USD ($)	Total	Member Units [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Preferred Stock [Member]
Beginning Balance at Dec. 31, 2014	$ (1,812,633)	$ 3,452,852		$ 0	$ (5,265,485)	$ 0
Beginning Balance (in shares) at Dec. 31, 2014		10,821,827				0
Fair value of warrants issued with convertible notes payable	16,656	$ 16,656		0	0	$ 0
Issuance of convertible notes payable - beneficial conversion feature	25,844	25,844		0	0	0
Issuance of common stock - conversion of notes payable, promissory notes payable and related interest	1,429,035	$ 1,429,035		0	0	$ 0
Issuance of common stock - conversion of notes payable, promissory notes payable and related interest (in shares)		2,659,294				0
Issuance of common stock as inducement to convert	1,135,356	$ 1,135,356		0	0	$ 0
Issuance of common stock as inducement to convert (in shares)		995,926				0
Issuance of warrants as inducement to convert	506,857	$ 506,857		0	0
Issuance of common stock for services	2,625,679	$ 2,625,679		0	0	$ 0
Issuance of common stock for services (in shares)		2,303,227				0
Issuance of common stock - warrant exercises	90,000	$ 90,000				$ 0
Issuance of common stock - warrant exercises (in shares)		450,000				0
Net loss	(5,094,421)	$ 0		0	(5,094,421)	$ 0
Ending Balance at Jun. 30, 2015			$ 0
Ending Balance (in shares) at Jun. 30, 2015			0
Beginning Balance at Dec. 31, 2014	(1,812,633)	$ 3,452,852		0	(5,265,485)	$ 0
Beginning Balance (in shares) at Dec. 31, 2014		10,821,827				0
Fair value of warrants issued with convertible notes payable	16,656
Net loss	(8,841,296)
Ending Balance at Dec. 31, 2015	(1,227,550)	$ 0	$ 21,911	12,857,320	(14,106,781)	$ 0
Ending Balance (in shares) at Dec. 31, 2015		0	21,911,396			0
Beginning Balance at Jun. 30, 2015			$ 0
Beginning Balance (in shares) at Jun. 30, 2015			0
Fair value of warrants issued with convertible notes payable	181,576		$ 0	181,576	0	$ 0
Issuance of common stock - conversion of notes payable, promissory notes payable and related interest	983,989		$ 1,290	982,699	0	$ 0
Issuance of common stock - conversion of notes payable, promissory notes payable and related interest (in shares)			1,328,346			0
Issuance of common stock as inducement to convert	57,397		$ 56	57,341	0	$ 0
Issuance of common stock as inducement to convert (in shares)			50,348			0
Issuance of common stock for services	2,263,804		$ 2,752	2,261,052	0	$ 0
Issuance of common stock for services (in shares)			2,719,091			0
Issuance of common stock - warrant exercises	78,333		$ 583	77,750	0	$ 0
Issuance of common stock - warrant exercises (in shares)			583,337			0
Conversion of membership units to common stock on June 30, 2015	0	$ (9,282,279)	$ 17,230	9,265,049	0	$ 0
Conversion of membership units to common stock on June 30, 2015 (in shares)		(17,230,274)	17,230,274			0
Fair value of warrants issued in conversion of accounts payable	31,853		$ 0	31,853	0	$ 0
Net loss	(3,746,875)		0	0	(3,746,875)	0
Ending Balance at Dec. 31, 2015	(1,227,550)	$ 0	$ 21,911	12,857,320	(14,106,781)	$ 0
Ending Balance (in shares) at Dec. 31, 2015		0	21,911,396			0
Fair value of warrants issued with convertible notes payable	270,076	$ 0	$ 0	270,076	0	$ 0
Issuance of common stock for services	1,425,684	$ 0	$ 740	1,424,944	0	$ 0
Issuance of common stock for services (in shares)		0	740,000			0
Fair value of warrants issued for services	344,846	$ 0	$ 0	344,846	0	$ 0
Fair value of post-maturity warrants issued as additional interest on notes payable	575,673	0	0	575,673	0	0
Issuance of common stock - conversion of accrued management fees	602,741	$ 0	$ 685	602,056	0	$ 0
Issuance of common stock - conversion of accrued management fees (in shares)		0	684,933			0
Issuance of preferred stock	1,170,000	$ 0	$ 0	1,168,830	0	$ 1,170
Issuance of preferred stock (in shares)		0	0			1,170,000
Fair value of preferred stock - conversion of notes payable and related interest	784,888	$ 0	$ 0	784,353	0	$ 535
Fair value of preferred stock - conversion of notes payable and related interest (in shares)		0	0			535,154
Fair value of common stock - conversion of notes payable and related interest	1,385,516	$ 0	$ 1,652	1,383,864	0	$ 0
Fair value of common stock - conversion of notes payable and related interest (in shares)		0	1,651,732			0
Issuance of convertible notes payable - beneficial conversion feature	70,949	$ 0	$ 0	70,949	0	$ 0
Accretion of beneficial conversion feature on preferred stock	0	0	0	760,011	(760,011)	0
Dividend on preferred stock	0	$ 0	$ 58	34,960	(35,018)	$ 0
Dividend on preferred (in shares)		0	58,377			0
Net loss	(5,748,397)	$ 0	$ 0	0	(5,748,397)	$ 0
Ending Balance at Dec. 31, 2016	$ (345,574)	$ 0	$ 25,046	$ 20,277,882	$ (20,650,207)	$ 1,705
Ending Balance (in shares) at Dec. 31, 2016		0	25,046,438			1,705,154

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net loss	$ (5,748,397)	$ (8,841,296)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	60,129	53,741
Amortization of debt discount	431,681	642,029
Change in fair value of note	698,147	0
Accrued interest expense included in notes payable	86,711	110,919
Fair value of warrants issued as post-maturity interest	575,673	0
Stock-based compensation	787,684	2,400,139
Stock-based compensation - related parties	982,846	2,485,450
Management fee compensation expense	191,781	0
Loss on settlement of promissory notes payable and accounts payable	249,739	258,606
Inducement expense on conversions of notes payable to equity	0	1,699,609
Warrants issued in payment of accounts payable	0	7,993
(Increase) decrease in -
Accounts receivable	(537)	(97)
Inventories	(13,436)	(6,335)
Deposits and prepaid expenses	14,587	(9,345)
Increase (decrease) in -
Accounts payable and accrued expenses	84,605	76,112
Accrued and deferred rent costs	(54,787)	(17,283)
Net cash used in operating activities	(1,653,574)	(1,139,758)
Investing Activities
Purchase of property and equipment	(3,354)	(2,162)
Net cash used in investing activities	(3,354)	(2,162)
Financing Activities
Proceeds from issuance of convertible notes payable	136,000	542,500
Proceeds from issuance of promissory notes - related party	140,000	200,000
Proceeds from issuance of promissory notes	220,000	100,000
Payments on promissory notes	(151,000)	0
Proceeds from issuance of preferred stock	1,145,000	0
Proceeds from exercise of warrants	0	75,000
Increase in due to related parties	215,598	232,110
Net cash provided by financing activities	1,705,598	1,149,610
Cash:
Net increase (decrease)	48,670	7,690
Balance at beginning of period	13,850	6,160
Balance at end of period	62,520	13,850
Supplemental disclosure of cash flow information:
Cash paid for - Interest	0	0
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Issuance of common stock upon conversion of accrued management fees	410,960	0
Issuance of preferred stock upon conversion of notes payable and related interest	535,149	0
Issuance of common stock upon conversion of notes payable and related interest	687,369	2,412,809
Fair value of warrants issued in connection with promissory and convertible notes payable	270,075	198,232
Beneficial conversion feature associated with promissory and convertible notes payable	70,949	25,844
Accrued interest on notes payable utilized to exercise warrants	0	93,333
Fair value of warrants issued in conversion of accounts payable	$ 0	$ 7,504

Organization and Business Opera

Organization and Business Operations	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business Operations Organization and Business Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z ® ® Through December 31, 2016, the Company has had limited operations, but has been primarily engaged in research and development and capital raising. The Company has incurred significant expenditures for the development of the Company's products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the years ended December 31, 2016 and 2015, all of which was generated by the sale of the Company’s proprietary product, Lumega-Z, during such periods. In late 2014, the Company changed its focus from the dietary supplement category to the medical food category based on consultation with the Company’s intellectual property counsel and regulatory affairs consultants, as a result of which Lumega-Z was categorized and sold as a medical food in 2015 and 2016. Going Concern and Liquidity The financial statements have been prepared assuming the Company will continue as a going concern. The Company has utilized cash in operating activities of $ 1,653,574 1,139,758 345,574 1,227,550 The Company’s auditors have also included explanatory language in their opinion that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s convertible notes payable and promissory notes approximates their carrying value given the interest rates of such notes. Cash balances are maintained at large, well-established financial institutions. At times, cash balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage limits are $ 250,000 The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period. Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of December 31, 2016 and 2015, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates. The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. when the risk of loss transfers to our customers, and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase. Product returns for the years ended December 31, 2016 and 2015 were insignificant. Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $ 64,026 401,909 The Company is the owner of one issued domestic patent, one pending domestic patent application, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and other costs, including internally generated costs, are expensed as incurred. During the years ended December 31, 2016 and 2015, patent costs were $ 30,942 26,407 When conventional convertible debt is issued with detachable warrants, the proceeds from issuance are allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt is issued with any other freestanding instrument that is classified in equity. When the convertible debt instrument includes both detachable instruments such as warrants, and a beneficial conversion option, the proceeds of issuance are allocated among the convertible instrument and the other detachable instruments based on their relative fair values as indicated above, and the amount allocated to the convertible instrument is further analyzed to determine if the embedded conversion option has intrinsic value. If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value, then the conversion option has intrinsic value and this feature is characterized as a beneficial conversion feature (“BCF”). The Company calculates an effective conversion price based on the fair value allocated to the convertible instrument divided by the number of conversion shares based upon the conversion terms of the instrument. The resulting calculation or effective conversion price is used to measure the intrinsic value, if any, of the embedded conversion option. Stated differently, intrinsic value is calculated at the commitment date as the difference between the conversion price (effective or otherwise) and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. A BCF is recorded by the Company as a debt discount and in those circumstances, the convertible debt will be recorded net of the discount related to the BCF. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method or the straight-line method, as an approximation of effective interest amortization. The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers and directors, and to employees which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future. The fair value of members’ units or common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, we retained a third-party valuation firm in determining the value of our Company. The third-party valuation firm’s input was utilized in determining the related per unit or share valuations of our equity used at December 31, 2016 and 2015. Management used valuations of $1.00 per unit or share in its fair value calculations for the periods between December 31, 2014 and September 30, 2016, and $0.88 per share for periods after September 30, 2016, respectively, based on various inputs, including valuation reports prepared by the third-party valuation firm as of December 31, 2016 and 2015. The fully diluted per share equivalent price is lower in 2016 than in 2015 due to the dilutive effect of the issuance of common shares as compensation during the period. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. We considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. Year Ended December 31, 2016 2015 Discount rate 16 % 16 % Risk free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0 Management considered business and market factors affecting the Company during the twelve-month periods ended December 31, 2016 and 2015, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that $ 0.88 1.00 The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The Company recognizes stock compensation expense on stock or unit purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock or units over the price paid for the stock or units. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises. The Company was a limited liability company prior to June 30, 2015, and taxed as a pass-through entity whereby substantially all income tax attributes were passed through to the individual members, except for the minimum state income tax and an LLC fee based on revenues. As of June 30, 2015, the Company became a corporation subject to U.S. federal income taxes and California state income taxes. The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. The Company considers membership units to be equivalent to common shares for purposes of the computation of net loss per share. Potential common shares such as from unexercised warrants and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. December 31, 2016 2015 Warrants 2,923,666 1,345,166 Estimated shares issuable upon conversion of convertible notes payable - 1,136,519 Shares issuable upon conversion of convertible preferred stock 2,841,930 - 5,765,596 2,481,685 In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventories December 31, 2016 2015 Raw materials $ 40,679 $ 26,534 Finished goods 3,320 4,029 $ 43,999 $ 30,563

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, net December 31, 2016 2015 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 145,503 145,503 Furniture and fixtures 15,348 15,189 Computer equipment 15,277 12,082 Office equipment 2,694 2,694 277,179 273,825 Less accumulated depreciation and amortization (163,159) (103,030) $ 114,020 $ 170,795 For the years ended December 31, 2016 and 2015, depreciation and amortization expense was $ 60,129 53,741 27,490 37,508 32,639 16,233

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2016
Convertible Notes Payable [Member]
Debt Disclosure [Text Block]	5. Convertible Notes Payable December 31, Year of issuance: 2016 2015 2010 (due August 2013) $ 25,000 $ 25,000 2015 (due May 2017) - 500,000 Accrued interest 19,323 32,890 Total principal and interest 44,323 557,890 Non-current portion of convertible notes payable - 516,575 Current portion of notes payable $ 44,323 $ 41,315 Notes Issued in 2016 and Converted During 2016, the Company issued convertible notes payable in the principal amount of $ 136,000 10 8 0.60 136,000 1.00 136,000 70,949 65,051 1.00 111 113 0.81 0.90 During 2016, the Company issued 242,878 145,724 136,000 2015 and Prior Issuances In July 2010, the Company issued an unsecured convertible note payable in the amount of $ 25,000 12 0.08 19,323 In May 2015, the Company issued a convertible note in the principal amount of $ 500,000 5 ⋅ The registration of any class of securities of the Borrower pursuant to an effective registration statement under the Securities Act of 1933, as amended; ⋅ The registration of any class of securities of the Borrower pursuant to an effective registration statement under the Securities Exchange Act of 1934, as amended; ⋅ The merger by and between the Company and an entity subject to the reporting obligations under the Securities Exchange Act of 1934, as amended, including both shell and non-shell companies; provided, however, that the Borrower and its equity holders must receive 50% or more of the equity interest in the Reporting Company immediately after the merger. Upon conversion of the principal amount of the note, the holder was entitled to an undiluted 4.76 On December 27, 2016, the Company received a Notice of Effectiveness from the SEC pursuant to its registration of common stock under the Securities Act of 1933, as amended. On December 31, 2016, the $ 500,000 41,644 1,408,854 1,239,792 0.88 698,147 As of December 31, 2014, the Company had outstanding $ 1,137,500 237,937 338,510 42,500 10 12 3 0.50 31,687 0.60 50 0.75 50 42,500 25,844 16,656 16,656 1.50 104 109 0.83 1.03 During 2015, the Company issued 1,793,692 986,542 119,972 886,988 480,833 143,971 In connection with the 2015 conversion of notes payable, the Company issued 995,926 1,135,356 146,000 165,072 1.14 113 0.97 50,348 57,397 1.14 381,009 As of December 31, 2014, the Company had Convertible notes payable of $ 400,000 114,693 12 0.45 0.55 In May 2015, the Company issued 865,602 442,493 350,001 341,785 1.14 113 0.97

Promissory Notes

Promissory Notes	12 Months Ended
	Dec. 31, 2016
Promissory Notes Payable [Member]
Debt Disclosure [Text Block]	6. Promissory Notes December 31, Year of issuance: 2016 2015 2015 (due June 2016) $ - $ 100,000 2016 (due November 2016) 10,000 - Accrued interest 251 425 Total principal and interest 10,251 100,425 Debt discount – unamortized balance - (36,018) Promissory notes payable, net $ 10,251 $ 64,407 2016 Issuances In 2016, the Company issued $ 170,000 4 9 187,500 0.25 0.50 87,627 183,753 1.00 111 116 0.91 1.06 50,000 8 50,000 0.25 24,726 48,917 1.00 122 0.87 220,000 210,000 In June of 2016, $ 100,000 110,000 5,462 115,462 169,344 53,882 10,000 251 2015 and Prior Issuances In November 2015, the Company issued a $ 100,000 100,000 0.25 49,339 97,392 1.14 101 1.24 13,321 100,000 8,836 108,836 159,626 50,790 As of December 31, 2014, the Company had outstanding promissory notes of $ 235,000 18,158 108,049 441,358 503,149 260,900 242,249

Promissory Notes - Related Part

Promissory Notes - Related Party	12 Months Ended
	Dec. 31, 2016
Investor [Member]
Debt Disclosure [Text Block]	7. Promissory Notes – Related Party December 31, Year of issuance: 2016 2015 2015 (due December 2015 through March 2016) $ - $ 200,000 2016 (due September 2016) 14,000 - Accrued interest 2,805 3,872 Total principal and interest 16,805 203,872 Debt discount – unamortized balance - (54,639) Promissory notes payable – related party, net $ 16,805 $ 149,233 2016 Issuances In 2016, the Company issued $ 140,000 280,000 0.25 0.50 92,671 272,748 1.00 109 113 0.93 1.31 During 2016, $ 51,000 75,000 7,833 82,834 121,490 38,657 14,000 2,805 2015 and Prior Issuances In 2015, the Company issued $ 200,000 400,000 0.25 0.50 132,237 390,292 1.14 100 105 0.92 1.33 200,000 28,019 228,021 334,431 106,412

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Operating Lease In October 2012, the Company entered into a lease agreement for 9,605 10,227 47,449 36,979 10,470 As of December 31, 2016 and 2015, the Company had accrued and deferred rent payable for its office and warehouse facilities under its lease agreement in the aggregate of $ 85,399 143,077 The approximate future minimum lease payments under non-cancelable operating leases at December 31, 2016 are as follows: Years ending December 31, 2017 $ 121,599 2018 72,710 $ 194,309 Rent expense was $ 106,217 106,217 Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. Stockholders’ Deficit As of December 31, 2016, the Company is authorized to issue is 100,000,000 90,000,000 0.001 10,000,000 0.001 25,046,438 On October 30, 2015, the Company amended its Certificate of Incorporation to change the par value of its common stock and preferred stock from $ 0.0001 0.001 On June 30, 2015 the Company changed its form of organization from a limited liability company to a corporation under the laws of the State of Delaware and all LLC membership units were converted to common stock on a one for one basis. The Company was previously governed by the terms and conditions of the Guardion Health Sciences, LLC Second Amended and Restated Operating Agreement dated January 28, 2012 (the “Operating Agreement”) and had one authorized class of units, and one class of members which consisted of four members. The LLC's business, property, and affairs were managed exclusively by the manager. Members' voting rights were in direct proportion to their Membership Interests. Preferred Stock 2016 During 2016, the Company sold 1,170,000 1.00 1,170,000 535,154 784,888 535,149 1.00 8 0.60 At the option of the holder, the Preferred Stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $ 0.60 The Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more. The issuance of the 1,170,000 shares of convertible preferred stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.60 per share being less than the market price of the shares at the issuance date as determined by a third-party valuation. The Company accounted for the beneficial conversion features in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series A Senior Convertible Preferred Stock of $ 779,586 760,011 19,575 The Preferred Stock will vote with the common stock on an “as converted” basis and has standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of the Preferred Stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the Preferred Stock, then the entire assets shall be distributed ratably among the holders of the Preferred Stock in accordance with the respective amounts that would be payable on such shares of Preferred Stock if all amounts payable thereon were paid in full. The Preferred Stock will be senior to any other classes or series of preferred stock that may subsequently be issued. Preferred shareholders have unlimited piggyback registration rights. Holders of a majority of the shares of Preferred Stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $ 500,000 250,000 In the event of a merger or acquisition or change in control of the Company, the Preferred Stock (including all accrued but unpaid dividends) will be deemed converted into shares of common stock immediately prior to the closing of such a transaction. Sale of the Company’s Series A Senior Convertible Preferred Stock was completed on December 31, 2016. There was no preferred stock issued during the year ended December 31, 2015. During the year ended December 31, 2016, the Company declared dividends of $ 35,018 58,377 Common Stock 2016 Prior to 2016, the Company issued 1,260,000 1,435,024 601,344 During 2016, the Company issued an additional 145,000 145,348 1.00 During 2016, the Company recorded $ 864,752 111,369 Number of Shares Weighted Average Non-vested, December 31, 2014 - $ - Issued 1,260,000 1.14 Vested (252,500) 1.14 Forfeited - - Non-vested, December 31, 2015 1,007,500 1.14 Issued 145,000 1.00 Vested (800,000) 1.12 Forfeited - - Non-vested, December 31, 2016 352,500 $ 1.13 During 2016, the Company also issued 595,000 560,932 During 2016, the Company issued 1,651,732 1,385,515 687,368 698,147 On December 31, 2016, the Company issued 684,933 602,741 410,960 191,781 2015 During 2015, the Company sold 2,303,227 2,303 2,625,679 1.14 2,623,376 1,459,091 1,662,676 1.14 Warrants 2016 During 2016, in connection with a related party investor’s short-term loan agreements with maturity dates ranging from December 29, 2015 to April 24, 2016, the Company agreed to issue interest in the form of warrants (the “post-maturity warrants”) in addition to the continued accrual of the stated interest ( 12 0.25 585,000 575,673 1.00 118 1.01 575,673 In May 2016, the Company issued warrants to purchase 250,000 0.25 246,341 1.00 116 1.08 246,341 In June 2016, the Company issued warrants to purchase 100,000 0.25 98,505 1.00 116 1.07 98,505 Membership Units or Shares December 31, 2014 1,317,894 Granted 1,832,916 Forfeitures (782,307) Exercised (1,033,337) December 31, 2015 1,335,166 Granted 1,588,500 December 31, 2016, all exercisable 2,923,666 Membership Weighted Average Outstanding at: Units or Shares Exercise Price December 31, 2014 1,317,894 $ 0.37 December 31, 2015 1,335,166 $ 0.56 December 31, 2016 2,923,666 $ 0.37 As of December 31, 2016, the Company had an aggregate of 2,923,666 1.4 1,285,712 0.88 2015 During 2015, in connection with the issuance of notes payable of $ 42,500 0.50 31,687 50 0.60 0.75 On May 1 2015, the Company issued warrants valued at $ 506,857 496,001 0.21 On May 1, 2015, the Company issued 450,000 0.20 90,000 During 2015, the Company issued 250,001 75,000 333,336 0.01 3,334 On August 10, 2015, the Company issued warrants to purchase 28,176 0.01 15,497 31,853 1.14 105 1.09 16,357

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	10. Related Party Transactions Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other shareholders. The advances are unsecured, non-interest bearing and are due on demand. As of December 31, 2016 and 2015, the Company had $ 91,483 286,844 The Company paid management fees directly to Michael Favish prior to the Company’s conversion to a corporation. During the first six months of 2015, the Company accrued management fees of $ 106,250 6,250 100,000 0 250,000 48,500 On December 31, 2016, the Company issued 684,933 602,741 410,960 191,781 On December 31, 2016, the Company awarded stock grants to its management and directors as compensation for services rendered. This included 50,000 20,000 15,000 5,000 162,800 As of December 31, 2016, $ 14,000 2,085 12 For the year ended December 31, 2015, the Company recorded $ 2,485,450 1,423,750 477,714 285,000 119,419 171,000 8,557

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11. Income Taxes December 31, 2016 2015 Net operating loss carryforwards $ 3,356,000 $ 1,414,000 Stock-based compensation 2,016,000 1,131,000 Deferred rent 9,000 11,000 Accrued compensation due to related party - 60,000 Depreciation 1,000 2,000 Total deferred tax assets 5,382,000 2,618,000 Valuation allowance (5,382,000) (2,618,000) Net deferred tax assets $ - $ - In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2016, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates. No federal tax provision has been provided for the years ended December 31, 2016 and 2015, due to the losses incurred during the period. Prior to July 1, 2015, the Company operated as a limited liability company, and as such, all profits, losses, revenues, expenses and other income tax attributes were passed through to the limited liability company owners. Year Ended December 31, 2016 2015 U. S. federal statutory tax rate (35.0) % (35.0) % Net losses passed through to owners while operating as a limited liability company 0.0 % 18.5 % State taxes, net of Federal benefit (6.0) % (6.0) % Change in valuation allowance 41.0 % 22.5 % Effective tax rate 0.0 % 0.0 % At December 31, 2016, the Company has available net operating loss carryforwards for federal income tax purposes of approximately $ 8,234,000 2035

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	12. Subsequent Events On January 31, 2017, the Company borrowed $ 100,000 6,000 On March 1, 2017, the Company entered into a non-binding letter of intent (“LOI”) with Vector Vision, Inc., a Delaware corporation (“VectorVision”), whereby the parties set forth an outline of the terms and conditions pursuant to which the Company would acquire all of the outstanding shares of stock of VectorVision in exchange for a to be determined number of shares of common stock of the Company. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. The transaction is subject to significant conditions precedent to closing, including, but not limited to, the satisfactory completion of due diligence, the determination of the amount of purchase consideration, the negotiation of definitive transaction documents, the completion of an audit of VectorVision’s financial statements, and other matters, no later than the June 30, 2017 expiration date of the LOI. On March 1, 2017, the Company issued 162,500 Between January 1, 2017 and March 13, 2017, the Company issued 700,000 700,000 1.00 6 0.75 5,000,000 2.00 60,000 0.75 March 6, 2020 March 8, 2020

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]	The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s convertible notes payable and promissory notes approximates their carrying value given the interest rates of such notes.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Cash balances are maintained at large, well-established financial institutions. At times, cash balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage limits are $ 250,000
Inventory, Policy [Policy Text Block]	The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	The Company reviews long-lived assets, consisting of property and equipment, for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of December 31, 2016 and 2015, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates.
Revenue Recognition, Policy [Policy Text Block]	The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. when the risk of loss transfers to our customers, and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase. Product returns for the years ended December 31, 2016 and 2015 were insignificant.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $ 64,026 401,909
Patent Costs Policy [Policy Text Block]	Patent Costs The Company is the owner of one issued domestic patent, one pending domestic patent application, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company's research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and other costs, including internally generated costs, are expensed as incurred. During the years ended December 31, 2016 and 2015, patent costs were $ 30,942 26,407
Debt, Policy [Policy Text Block]	When conventional convertible debt is issued with detachable warrants, the proceeds from issuance are allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt is issued with any other freestanding instrument that is classified in equity. When the convertible debt instrument includes both detachable instruments such as warrants, and a beneficial conversion option, the proceeds of issuance are allocated among the convertible instrument and the other detachable instruments based on their relative fair values as indicated above, and the amount allocated to the convertible instrument is further analyzed to determine if the embedded conversion option has intrinsic value. If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value, then the conversion option has intrinsic value and this feature is characterized as a beneficial conversion feature (“BCF”). The Company calculates an effective conversion price based on the fair value allocated to the convertible instrument divided by the number of conversion shares based upon the conversion terms of the instrument. The resulting calculation or effective conversion price is used to measure the intrinsic value, if any, of the embedded conversion option. Stated differently, intrinsic value is calculated at the commitment date as the difference between the conversion price (effective or otherwise) and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. A BCF is recorded by the Company as a debt discount and in those circumstances, the convertible debt will be recorded net of the discount related to the BCF. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method or the straight-line method, as an approximation of effective interest amortization.
Compensation Related Costs, Policy [Policy Text Block]	The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers and directors, and to employees which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future. The fair value of members’ units or common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, we retained a third-party valuation firm in determining the value of our Company. The third-party valuation firm’s input was utilized in determining the related per unit or share valuations of our equity used at December 31, 2016 and 2015. Management used valuations of $1.00 per unit or share in its fair value calculations for the periods between December 31, 2014 and September 30, 2016, and $0.88 per share for periods after September 30, 2016, respectively, based on various inputs, including valuation reports prepared by the third-party valuation firm as of December 31, 2016 and 2015. The fully diluted per share equivalent price is lower in 2016 than in 2015 due to the dilutive effect of the issuance of common shares as compensation during the period. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. We considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. Year Ended December 31, 2016 2015 Discount rate 16 % 16 % Risk free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0 Management considered business and market factors affecting the Company during the twelve-month periods ended December 31, 2016 and 2015, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that $ 0.88 1.00 The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The Company recognizes stock compensation expense on stock or unit purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock or units over the price paid for the stock or units. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.
Income Tax, Policy [Policy Text Block]	The Company was a limited liability company prior to June 30, 2015, and taxed as a pass-through entity whereby substantially all income tax attributes were passed through to the individual members, except for the minimum state income tax and an LLC fee based on revenues. As of June 30, 2015, the Company became a corporation subject to U.S. federal income taxes and California state income taxes. The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. The Company considers membership units to be equivalent to common shares for purposes of the computation of net loss per share. Potential common shares such as from unexercised warrants and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. December 31, 2016 2015 Warrants 2,923,666 1,345,166 Estimated shares issuable upon conversion of convertible notes payable - 1,136,519 Shares issuable upon conversion of convertible preferred stock 2,841,930 - 5,765,596 2,481,685
New Accounting Pronouncements, Policy [Policy Text Block]	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions: Year Ended December 31, 2016 2015 Discount rate 16 % 16 % Risk free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: December 31, 2016 2015 Warrants 2,923,666 1,345,166 Estimated shares issuable upon conversion of convertible notes payable - 1,136,519 Shares issuable upon conversion of convertible preferred stock 2,841,930 - 5,765,596 2,481,685

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consisted of the following: December 31, 2016 2015 Raw materials $ 40,679 $ 26,534 Finished goods 3,320 4,029 $ 43,999 $ 30,563

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following: December 31, 2016 2015 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 145,503 145,503 Furniture and fixtures 15,348 15,189 Computer equipment 15,277 12,082 Office equipment 2,694 2,694 277,179 273,825 Less accumulated depreciation and amortization (163,159) (103,030) $ 114,020 $ 170,795

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Convertible Notes Payable [Member]
Convertible Debt [Table Text Block]	December 31, Year of issuance: 2016 2015 2010 (due August 2013) $ 25,000 $ 25,000 2015 (due May 2017) - 500,000 Accrued interest 19,323 32,890 Total principal and interest 44,323 557,890 Non-current portion of convertible notes payable - 516,575 Current portion of notes payable $ 44,323 $ 41,315

Promissory Notes (Tables)

Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2016
Promissory Notes Payable [Member]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, Year of issuance: 2016 2015 2015 (due June 2016) $ - $ 100,000 2016 (due November 2016) 10,000 - Accrued interest 251 425 Total principal and interest 10,251 100,425 Debt discount – unamortized balance - (36,018) Promissory notes payable, net $ 10,251 $ 64,407

Promissory Notes - Related Pa25

Promissory Notes - Related Party (Tables)	12 Months Ended
	Dec. 31, 2016
Investor [Member]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, Year of issuance: 2016 2015 2015 (due December 2015 through March 2016) $ - $ 200,000 2016 (due September 2016) 14,000 - Accrued interest 2,805 3,872 Total principal and interest 16,805 203,872 Debt discount – unamortized balance - (54,639) Promissory notes payable – related party, net $ 16,805 $ 149,233

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The approximate future minimum lease payments under non-cancelable operating leases at December 31, 2016 are as follows: Years ending December 31, 2017 $ 121,599 2018 72,710 $ 194,309

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Nonvested Restricted Stock Shares Activity [Table Text Block]	Additional details of the Company’s restricted common stock are as follows: Number of Shares Weighted Average Non-vested, December 31, 2014 - $ - Issued 1,260,000 1.14 Vested (252,500) 1.14 Forfeited - - Non-vested, December 31, 2015 1,007,500 1.14 Issued 145,000 1.00 Vested (800,000) 1.12 Forfeited - - Non-vested, December 31, 2016 352,500 $ 1.13
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the Company’s warrant activity is as follows: Membership Units or Shares December 31, 2014 1,317,894 Granted 1,832,916 Forfeitures (782,307) Exercised (1,033,337) December 31, 2015 1,335,166 Granted 1,588,500 December 31, 2016, all exercisable 2,923,666
Schedule of Outstanding Warrants [Table Text Block]	Additional details of the Company’s outstanding and exercisable warrants are as follows: Membership Weighted Average Outstanding at: Units or Shares Exercise Price December 31, 2014 1,317,894 $ 0.37 December 31, 2015 1,335,166 $ 0.56 December 31, 2016 2,923,666 $ 0.37

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	As of December 31, 2016 and 2015, significant components of the Company’s deferred tax assets were as follows: December 31, 2016 2015 Net operating loss carryforwards $ 3,356,000 $ 1,414,000 Stock-based compensation 2,016,000 1,131,000 Deferred rent 9,000 11,000 Accrued compensation due to related party - 60,000 Depreciation 1,000 2,000 Total deferred tax assets 5,382,000 2,618,000 Valuation allowance (5,382,000) (2,618,000) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rates for the years ended December 31, 2016 and 2015: Year Ended December 31, 2016 2015 U. S. federal statutory tax rate (35.0) % (35.0) % Net losses passed through to owners while operating as a limited liability company 0.0 % 18.5 % State taxes, net of Federal benefit (6.0) % (6.0) % Change in valuation allowance 41.0 % 22.5 % Effective tax rate 0.0 % 0.0 %

Organization and Business Ope29

Organization and Business Operations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$ (1,653,574)	$ (1,139,758)
Stockholders' Equity Attributable to Parent, Total	345,574
Members' Equity, Total	$ (345,574)	$ (1,227,550)	$ (1,812,633)

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Discount rate	16.00%	16.00%
Risk free rate	2.48%	2.27%
Rate of return	16.00%	16.00%
Sustainable growth rate	5.00%	5.00%
Company survival probability	65.00%	63.00%
Liquidation value	$ 0	$ 0

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,765,596	2,481,685
Conversion of Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,841,930	0
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,136,519
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,923,666	1,345,166

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Aug. 10, 2015
Research and Development Expense	$ 64,026	$ 401,909
Insurance Coverage Limits	$ 250,000
Share Price	$ 0.88	$ 1	$ 1.14
Minimum [Member]
Property, Plant and Equipment, Estimated Useful Lives	three years
Maximum [Member]
Property, Plant and Equipment, Estimated Useful Lives	seven years
Patents [Member]
Research and Development Expense	$ 30,942	$ 26,407

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Raw materials	$ 40,679	$ 26,534
Finished goods	3,320	4,029
Inventory, Net, Total	$ 43,999	$ 30,563

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Gross, Total	$ 277,179	$ 273,825
Less accumulated depreciation and amortization	(163,159)	(103,030)
Property, Plant and Equipment, Net, Total	114,020	170,795
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	2,694	2,694
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	15,277	12,082
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	145,503	145,503
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	$ 15,348	$ 15,189

Property and Equipment, net (35

Property and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 60,129	$ 53,741
Research and Development Expense	64,026	401,909
General and Administrative Expense, Total	3,308,144	5,610,830
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total	60,129	53,741
Research and Development Expense	27,490	37,508
General and Administrative Expense, Total	$ 32,639	$ 16,233

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Non-current portion of convertible notes payable	$ 0	$ 516,575
Convertible Notes Payable [Member]
Debt Instrument, Face Amount	136,000
Current portion of notes payable			$ 400,000
Convertible Notes Payable [Member] | Unsecured Notes Payable [Member]
Accrued interest	19,323	32,890
Total principal and interest	44,323	557,890
Non-current portion of convertible notes payable	0	516,575
Current portion of notes payable	44,323	41,315
Convertible Notes Payable [Member] | Due August 2013 [Member] | Unsecured Notes Payable [Member]
Debt Instrument, Face Amount	25,000	25,000
Convertible Notes Payable [Member] | Due May 2017 [Member] | Unsecured Notes Payable [Member]
Debt Instrument, Face Amount	$ 0	$ 500,000

Convertible Notes Payable (De37

Convertible Notes Payable (Details Textual) - USD ($)	Aug. 10, 2015	Aug. 31, 2015	May 31, 2015	Jul. 31, 2010	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Amortization of Debt Discount (Premium)							$ 431,681	$ 642,029
Interest Expense, Debt							86,711	110,919
Proceeds from Convertible Debt							136,000	542,500
Debt Conversion, Converted Instrument, Amount					$ 181,576	$ 16,656	$ 270,076	$ 16,656
Debt Conversion, Converted Instrument, Warrants or Options Issued								31,687
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 31,853
Share Price	$ 1.14				$ 1		$ 0.88	$ 1
Fair Value Assumptions, Expected Volatility Rate	105.00%
Fair Value Assumptions, Risk Free Interest Rate	1.09%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	28,176		496,001
Percentage of Units Issued Upon Conversion of Notes								50.00%
Notes Payable, Fair Value Disclosure							$ 1,239,792
Gain (Loss) on Repurchase of Debt Instrument							(698,147)	$ 0
Convertible Debt [Member]
Convertible Debt And Interest Before Unamortized Debt Discount									$ 1,137,500
Amortization of Debt Discount (Premium)								42,500
Warrants Not Settleable in Cash, Fair Value Disclosure					$ 25,844			$ 25,844
Debt Instrument, Unamortized Discount									338,510
Interest Payable									$ 237,937
Unsecured Debt [Member]
Proceeds from Convertible Debt							500,000
Interest Payable							$ 41,644
Minimum [Member] | Convertible Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate								0.83%
Maximum [Member] | Convertible Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate								1.03%
Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.00%				10.00%		12.00%
Debt Instrument, Convertible, Conversion Price					$ 0.50		$ 0.60	$ 0.50
Amortization of Debt Discount (Premium)							$ 136,000
Interest Expense, Debt	$ 143,971							$ 119,972	$ 114,693
Proceeds from Convertible Debt			$ 500,000
Debt Instrument, Term							8 months	3 years
Debt Conversion, Converted Instrument, Shares Issued			865,602					1,793,692
Debt Conversion, Converted Instrument, Amount								$ 986,542
Debt Conversion, Converted Instrument, Warrants or Options Issued								146,000
Warrants Not Settleable in Cash, Fair Value Disclosure					$ 165,072		$ 70,949	$ 165,072
Share Price			$ 1.14		$ 1.14		$ 1	$ 1.14
Fair Value Assumptions, Expected Volatility Rate								113.00%
Fair Value Assumptions, Risk Free Interest Rate								0.97%
Debt Instrument, Face Amount							$ 136,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							136,000
Debt Instrument, Unamortized Discount							$ 136,000
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 65,051	$ 16,656
Stock Issued During Period, Shares, Conversion of Convertible Securities	886,988						242,878	995,926
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 480,833						$ 145,724	$ 1,135,356
Percentage of Undiluted							0.00%
Percentage of Units Issued Upon Conversion of Notes								50.00%
Convertible Notes Payable									$ 400,000
Convertible Notes Payable [Member] | Warrants 50 Percentage1 [Member]
Debt Instrument, Convertible, Conversion Price					0.60			$ 0.60
Convertible Notes Payable [Member] | Warrants 50 Percentage2 [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.75			$ 0.75
Convertible Notes Payable [Member] | Note Agreements [Member]
Debt Instrument, Convertible, Conversion Price		$ 1.14
Interest Expense, Debt		$ 381,009
Stock Issued During Period, Shares, Conversion of Convertible Securities		50,348
Stock Issued During Period, Value, Conversion of Convertible Securities		$ 57,397
Convertible Notes Payable [Member] | Unsecured Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage				12.00%
Debt Instrument, Convertible, Conversion Price				$ 0.08
Proceeds from Convertible Debt				$ 25,000
Stock Issued During Period, Shares, Conversion of Convertible Securities							1,408,854
Interest Payable							$ 19,323
Convertible Notes Payable [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage					10.00%			10.00%
Debt Instrument, Convertible, Conversion Price									$ 0.45
Fair Value Assumptions, Expected Volatility Rate							111.00%	104.00%
Fair Value Assumptions, Risk Free Interest Rate							0.81%
Convertible Notes Payable [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage					12.00%			12.00%
Debt Instrument, Convertible, Conversion Price									$ 0.55
Fair Value Assumptions, Expected Volatility Rate							113.00%	109.00%
Fair Value Assumptions, Risk Free Interest Rate							0.90%
Percentage of Units Issued Upon Conversion of Notes								50.00%

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Unsecured Promissory Notes [Member]
Accrued interest	$ 41,644
Notes Payable, Other Payables [Member] | Unsecured Promissory Notes [Member]
Accrued interest	251	$ 425
Total principal and interest	10,251	100,425
Debt discount - unamortized balance	0	(36,018)
Promissory notes payable, net	10,251	64,407
Notes Payable, Other Payables [Member] | 2016 (due June 2016) [Member]
Debt Instrument, Face Amount	0	100,000
Notes Payable, Other Payables [Member] | 2016 (due November 2016)
Debt Instrument, Face Amount	$ 10,000	$ 0

Promissory Notes (Details Textu

Promissory Notes (Details Textual) - USD ($)	Aug. 10, 2015	Aug. 31, 2016	Nov. 30, 2015	Aug. 31, 2015	May 31, 2016	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Amortization of Debt Discount (Premium)									$ 431,681	$ 642,029
Interest Expense, Debt									86,711	110,919
Proceeds from Notes Payable									220,000	$ 100,000
Debt Conversion, Converted Instrument, Warrants or Options Issued										31,687
Fair Value Assumptions, Expected Volatility Rate	105.00%
Fair Value Assumptions, Risk Free Interest Rate	1.09%
Debt Conversion, Converted Instrument, Amount							$ 181,576	$ 16,656	$ 270,076	$ 16,656
Share Price	$ 1.14						$ 1		$ 0.88	$ 1
Short-term Debt									$ 14,000
Debt Conversion, Original Debt, Amount									535,149
Notes Payable, Fair Value Disclosure									1,239,792
Gains (Losses) on Extinguishment of Debt, Total									(249,739)	$ (258,606)
2016 Issuances [Member]
Proceeds from Notes Payable					$ 183,753				272,748
Short-term Debt									10,000
Interest Payable, Current									251
Notes Payable, Fair Value Disclosure									169,344
Gains (Losses) on Extinguishment of Debt, Total									53,882
2015 Issuances [Member]
Proceeds from Notes Payable			$ 97,392							$ 390,292
Notes Payable, Fair Value Disclosure									159,626
Gains (Losses) on Extinguishment of Debt, Total									50,790
Preferred Stock [Member]
Debt Conversion, Converted Instrument, Amount							$ 0	$ 0	0
Notes Payable, Other Payables [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Amortization of Debt Discount (Premium)		$ 24,726							187,500
Interest Expense, Debt		220,000
Proceeds from Notes Payable		$ 50,000							$ 170,000
Debt Conversion, Converted Instrument, Warrants or Options Issued		50,000							87,627
Debt Instrument, Convertible, Conversion Price									$ 1
Fair Value Assumptions, Expected Volatility Rate									122.00%
Fair Value Assumptions, Risk Free Interest Rate									0.87%
Stock Issued During Period, Shares, Conversion of Convertible Securities									115,462
Stock Issued During Period, Value, Conversion of Convertible Securities		$ 210,000
Debt Conversion, Converted Instrument, Amount									$ 110,000
Share Price		$ 0.25							$ 1
Repayments of Short-term Debt						$ 100,000
Interest Payable, Current									$ 5,462
Notes Payable, Other Payables [Member] | 2015 Issuances [Member]
Amortization of Debt Discount (Premium)			100,000						13,321
Proceeds from Notes Payable			$ 100,000
Debt Conversion, Converted Instrument, Warrants or Options Issued			49,339
Debt Instrument, Convertible, Conversion Price			$ 0.25
Fair Value Assumptions, Expected Volatility Rate			101.00%
Fair Value Assumptions, Risk Free Interest Rate			1.24%
Stock Issued During Period, Shares, Conversion of Convertible Securities				441,358
Stock Issued During Period, Value, Conversion of Convertible Securities				$ 503,149
Debt Conversion, Converted Instrument, Amount				260,900
Loss on Settlement of Debt				$ 242,249
Share Price			$ 1.14
Interest Payable, Current			$ 8,836
Long-term Debt, Gross											$ 235,000
Interest Payable											18,158
Debt Instrument, Unamortized Discount											$ 108,049
Debt Conversion, Original Debt, Amount									$ 100,000
Notes Payable, Other Payables [Member] | Preferred Stock [Member] | 2015 Issuances [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities			108,836
Notes Payable, Other Payables [Member] | Minimum [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage									4.00%
Debt Instrument, Convertible, Conversion Price									$ 0.25
Fair Value Assumptions, Expected Volatility Rate									111.00%
Fair Value Assumptions, Risk Free Interest Rate									0.91%
Notes Payable, Other Payables [Member] | Maximum [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage									9.00%
Debt Instrument, Convertible, Conversion Price									$ 0.50
Fair Value Assumptions, Expected Volatility Rate									116.00%
Fair Value Assumptions, Risk Free Interest Rate									1.06%

Promissory Notes - Related Pa40

Promissory Notes - Related Party (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Unsecured Debt [Member]
Accrued interest	$ 41,644
Investor [Member]
Accrued interest	2,805	$ 3,872
Total principal and interest	16,805	203,872
Debt discount - unamortized balance	0	(54,639)
Promissory notes payable - related party, net	16,805	149,233
2015 (due December 2015 through March 2016) | Investor [Member] | Unsecured Debt [Member]
Debt Instrument, Face Amount	0	200,000
2016 (due September 2016) [Member] | Investor [Member] | Unsecured Debt [Member]
Accrued interest	$ 14,000	$ 0

Promissory Notes - Related Pa41

Promissory Notes - Related Party (Details Textual) - USD ($)	Aug. 10, 2015	Nov. 30, 2015	May 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Proceeds from Notes Payable				$ 220,000	$ 100,000
Amortization of Debt Discount (Premium)				$ 431,681	$ 642,029
Debt Conversion, Converted Instrument, Warrants or Options Issued					31,687
Share Price	$ 1.14			$ 0.88	$ 1
Fair Value Assumptions, Expected Volatility Rate	105.00%
Fair Value Assumptions, Risk Free Interest Rate	1.09%
Debt Conversion, Original Debt, Amount				$ 535,149
Short-term Debt				14,000
Notes Payable, Fair Value Disclosure				1,239,792
Gains (Losses) on Extinguishment of Debt, Total				(249,739)	$ (258,606)
2016 Issuances [Member]
Proceeds from Notes Payable			$ 183,753	272,748
Interest Payable, Current				251
Short-term Debt				10,000
Notes Payable, Fair Value Disclosure				169,344
Gains (Losses) on Extinguishment of Debt, Total				53,882
2015 Issuances [Member]
Proceeds from Notes Payable		$ 97,392			390,292
Notes Payable, Fair Value Disclosure				159,626
Gains (Losses) on Extinguishment of Debt, Total				50,790
Investor [Member] | 2016 Issuances [Member]
Proceeds from Notes Payable				140,000
Amortization of Debt Discount (Premium)				$ 280,000
Debt Conversion, Converted Instrument, Warrants or Options Issued				92,671
Share Price				$ 1
Repayments of Short-term Debt				$ 51,000
Debt Conversion, Original Debt, Amount				75,000
Interest Payable, Current				2,805
Notes Payable, Fair Value Disclosure				121,490
Gains (Losses) on Extinguishment of Debt, Total				38,657
Investor [Member] | 2015 Issuances [Member]
Proceeds from Notes Payable					200,000
Amortization of Debt Discount (Premium)					$ 400,000
Debt Conversion, Converted Instrument, Warrants or Options Issued					132,237
Share Price					$ 1.14
Debt Conversion, Original Debt, Amount				200,000
Interest Payable, Current				$ 28,019
Stock Issued During Period, Shares, Conversion of Convertible Securities				228,021
Notes Payable, Fair Value Disclosure					$ 334,431
Gains (Losses) on Extinguishment of Debt, Total					$ 106,412
Investor [Member] | Preferred Stock [Member] | 2016 Issuances [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities				82,834
Investor [Member] | Minimum [Member] | 2016 Issuances [Member]
Debt Instrument, Convertible, Conversion Price				$ 0.25
Fair Value Assumptions, Expected Volatility Rate				109.00%
Fair Value Assumptions, Risk Free Interest Rate				0.93%
Investor [Member] | Minimum [Member] | 2015 Issuances [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.25
Fair Value Assumptions, Expected Volatility Rate					100.00%
Fair Value Assumptions, Risk Free Interest Rate					0.92%
Investor [Member] | Maximum [Member] | 2016 Issuances [Member]
Debt Instrument, Convertible, Conversion Price				$ 0.50
Fair Value Assumptions, Expected Volatility Rate				113.00%
Fair Value Assumptions, Risk Free Interest Rate				1.31%
Investor [Member] | Maximum [Member] | 2015 Issuances [Member]
Debt Instrument, Convertible, Conversion Price					$ 0.50
Fair Value Assumptions, Expected Volatility Rate					105.00%
Fair Value Assumptions, Risk Free Interest Rate					1.33%

Commitments and Contingencies42

Commitments and Contingencies (Details)	Dec. 31, 2016USD ($)
2,017	$ 121,599
2,018	72,710
Operating Leases, Future Minimum Payments Due, Total	$ 194,309

Commitments and Contingencies43

Commitments and Contingencies (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Oct. 31, 2012ft²
Average Monthly Lease Payments	$ 10,227
Deposit Paid for Lease	47,449
Deposit Paid for Prepaid Rent	36,979
Deposit On Lease Agreement	10,470
Deferred Rent Credit	85,399	$ 143,077
Operating Leases, Rent Expense	$ 106,217	$ 106,217
Area of Land | ft²			9,605

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Number of Shares, Beginning Balance	1,007,500	0
Number of Shares, Issued	145,000	1,260,000
Number of Shares, Vested	(800,000)	(252,500)
Number of Shares, Forfeited	0	0
Number of Shares, Ending Balance	352,500	1,007,500
Weighted Average Grant Date Fair Value Per Share, Beginning Balance	$ 1.14	$ 0
Weighted Average Grant Date Fair Value Per Share, Issued	1	1.14
Weighted Average Grant Date Fair Value Per Share, Vested	1.12	1.14
Weighted Average Grant Date Fair Value Per Share, Forfeited	0	0
Weighted Average Grant Date Fair Value Per Share, Ending Balance	$ 1.13	$ 1.14

Stockholders' Deficit (Details

Stockholders' Deficit (Details 1) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Membership Units or Shares, Balance	1,335,166	1,317,894
Membership Units or Shares, Granted	1,588,500	1,832,916
Membership Units or Shares, Forfeitures		(782,307)
Membership Units or Shares, Exercised		(1,033,337)
Membership Units or Shares, Balance	2,923,666	1,335,166

Stockholders' Deficit (Detail46

Stockholders' Deficit (Details 2) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Aug. 10, 2015	May 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Membership Units or Shares, Outstanding	2,923,666	1,335,166			1,317,894
Weighted Average Exercise Price, Outstanding	$ 0.37	$ 0.56	$ 0.01	$ 0.21	$ 0.37

Stockholders' Deficit (Detail47

Stockholders' Deficit (Details Textual) - USD ($)	Aug. 10, 2015	Jun. 30, 2016	May 31, 2016	May 31, 2015	Mar. 13, 2017	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Jan. 31, 2017	Mar. 31, 2016	Oct. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Common Stock and Preferred Stock Authorized								100,000,000	100,000,000
Common Stock, Shares Authorized								90,000,000	90,000,000	90,000,000
Common Stock, Par or Stated Value Per Share								$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized								10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share								$ 0.001	$ 0.001
Common Stock, Shares, Issued								25,046,438	25,046,438	21,911,396
Units Issued Price Per Share to Investors										$ 1.14
Units Issued to Consultants										2,303,227
Units Issued Value to Consultants										$ 2,303
Units Fair Value										2,625,679
Share-based Compensation									$ 787,684	$ 2,400,139
Stock Issued During Period Shares Exercise of Warrants										250,001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	28,176			496,001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01			$ 0.21				$ 0.37	$ 0.37	$ 0.56				$ 0.37
Proceeds from Convertible Debt									$ 136,000	$ 542,500
Debt Conversion, Converted Instrument, Warrants or Options Issued										31,687
Percentage of Units Issued Upon Conversion of Notes										50.00%
Warrants and Rights Outstanding				$ 506,857
Units Issued During Period				450,000
Units Issued Weighted Average Exercise Price				$ 0.20		$ 0.01
Units Issued Value During Period				$ 90,000		$ 3,334
Repayments of Other Short-term Debt	$ 15,497
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 31,853
Fair Value Assumptions, Expected Volatility Rate	105.00%
Fair Value Assumptions, Risk Free Interest Rate	1.09%
Loss on Settlement of Accounts Payable	$ 16,357
Class of Warrant or Right, Outstanding								2,923,666	2,923,666	1,335,166				1,317,894
Warrants Weighted Average Remaining Life									1 year 4 months 24 days
Warrants Intrinsic Value									$ 1,285,712
Share Price	$ 1.14							$ 0.88	$ 0.88	$ 1
Preferred Stock, Dividends Per Share, Declared								$ 779,586
Accretion of Dividends								$ 760,011	$ 760,011
Debt Conversion, Original Debt, Amount									$ 535,149
Common Stock Dividends, Shares									58,377
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate									2.48%	2.27%
Interest Expense, Total									$ 1,104,557	$ 752,948
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate									16.00%	16.00%
Warrants Term				3 years
Stock Issued									$ 410,960	$ 0
Restricted Stock or Unit Expense										601,344
Gain (Loss) on Repurchase of Debt Instrument									$ (698,147)	$ 0
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services										1,260,000
Stock Issued During Period, Value, Issued for Services										$ 1,435,024
Share Price								$ 1	$ 1
Stock Issued During Period, Shares, New Issues									145,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period									145,000	1,260,000
Restricted Stock or Unit Expense									$ 864,752	$ 864,752
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									145,348
Stock Issued During Period, Value, Conversion of Convertible Securities									111,369
Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock									$ 35,018
Share-based Compensation Award, Tranche One [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period Shares Exercise of Warrants							333,336
Units Issued Value During Period							$ 75,000
Post-Maturity Warrants [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation		$ 98,505	$ 246,341
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,000	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25	$ 0.25					0.25	$ 0.25
Share Price		$ 1	$ 1					$ 1	$ 1
Debt Instrument, Interest Rate, Stated Percentage								12.00%	12.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period									585,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 98,505	$ 246,341						$ 575,673
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate									118.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.07%	1.08%						1.01%
Interest Expense, Total									$ 575,673
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		116.00%	116.00%
Common Stock [Member]
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share													$ 0.0001
Share-based Compensation									$ 560,932
Stock Issued During Period, Shares, Issued for Services									595,000	1,459,091
Stock Issued During Period, Value, Issued for Services										$ 1,662,676
Share Price										$ 1.14
Stock Issued During Period, Shares, New Issues									684,933
Stock Issued During Period, Value, New Issues									$ 191,781
Debt Conversion, Original Debt, Amount									$ 687,368
Convertible Common Stock, Conversion Price								$ 602,741	$ 602,741
Accrued Professional Fees								$ 410,960	$ 410,960
Debt Conversion, Converted Instrument, Shares Issued									1,651,732
Stock Issued									$ 1,385,515
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Preferred Stock, Par or Stated Value Per Share													$ 0.001
Debt Conversion, Converted Instrument, Shares Issued									535,154
Stock Issued									$ 784,888
Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services					162,500
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.75
Accretion of Dividends											$ 19,575
Convertible Notes Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								136,000	136,000
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 1
Proceeds from Convertible Debt				$ 500,000
Debt Instrument, Convertible, Conversion Price								$ 0.60	$ 0.60	$ 0.50
Debt Conversion, Converted Instrument, Warrants or Options Issued										146,000
Percentage of Units Issued Upon Conversion of Notes										50.00%
Warrants Not Settleable in Cash, Fair Value Disclosure								$ 70,949	$ 70,949	$ 165,072
Fair Value Assumptions, Expected Volatility Rate										113.00%
Fair Value Assumptions, Risk Free Interest Rate										0.97%
Share Price				$ 1.14				$ 1	$ 1	$ 1.14
Debt Instrument, Interest Rate, Stated Percentage				5.00%				10.00%	10.00%					12.00%
Debt Conversion, Converted Instrument, Shares Issued				865,602						1,793,692
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 480,833								$ 145,724	$ 1,135,356
Convertible Notes Payable [Member] | Warrants 50 Percentage1 [Member]
Class of Warrant or Right [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 0.60
Convertible Notes Payable [Member] | Warrants 50 Percentage2 [Member]
Class of Warrant or Right [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 0.75
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Preferred Stock, Par or Stated Value Per Share								$ 1	$ 1
Shares Issued, Price Per Share								$ 1	1
Stock Issued During Period, Shares, New Issues								1,170,000
Stock Issued During Period, Value, New Issues								$ 1,170,000
Preferred Stock, Dividend Rate, Percentage								8.00%
Preferred Stock, Dividends Per Share, Declared								$ 0.60
Convertible Preferred Stock, Conversion Price								$ 0.60	$ 0.60
Convertible Preferred Stock, Terms of Conversion								The Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.
Preferred Stock, Value, Outstanding								$ 250,000	$ 250,000
Series A Preferred Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues								$ 500,000

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 286,844		$ 91,483	$ 286,844
Debt Conversion, Converted Instrument, Amount	181,576	$ 16,656	270,076	16,656
Share-based Compensation			$ 787,684	2,400,139
Common Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues			684,933
Debt Conversion, Converted Instrument, Amount	0		$ 0
Stock Issued During Period, Value, New Issues			191,781
Stock Issued During Period, Value, Issued for Services				$ 1,662,676
Share-based Compensation			$ 560,932
Stock Issued During Period, Shares, Issued for Services			595,000	1,459,091
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount			$ 410,960
Stock Issued During Period, Shares, Issued for Services			50,000
Chief Executive Officer [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues			684,933
Stock Issued During Period, Value, New Issues			$ 602,741
Vice President [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services				$ 119,419
Stock Issued During Period, Shares, Issued for Services			20,000
General Counsel and Corporate Secretary [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services			15,000
Controller [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services			5,000
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Accrued Salaries, Current	100,000		$ 250,000	100,000
Payments to Employees	$ 0		48,500
Share-based Compensation			191,781
General and Administrative Expense [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Management Fee Payable		106,250
Payment for Management Fee		$ 6,250
Terrence Favish [Member]
Related Party Transaction [Line Items]
Notes Payable, Total			14,000
Interest Payable			$ 2,085
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Robert Weingarten [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services				1,423,750
Mark Goldstone [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services				477,714
Karen M. Favish [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services				285,000
Vincent J. Roth [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services				171,000
Marie Powell [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services				$ 8,557
Stock Based Compensation Award [Member]
Related Party Transaction [Line Items]
Share-based Compensation			$ 162,800

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Net operating loss carryforwards	$ 3,356,000	$ 1,414,000
Stock-based compensation	2,016,000	1,131,000
Deferred rent	9,000	11,000
Accrued compensation due to related party	0	60,000
Depreciation	1,000	2,000
Total deferred tax assets	5,382,000	2,618,000
Valuation allowance	(5,382,000)	(2,618,000)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
U. S. federal statutory tax rate	(35.00%)	(35.00%)
Net losses passed through to owners while operating as a limited liability company	0.00%	18.50%
State taxes, net of Federal benefit	(6.00%)	(6.00%)
Change in valuation allowance	41.00%	22.50%
Effective tax rate	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 8,234,000
Operating Loss Carryforwards Expiration Year	2,035

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
	Jan. 31, 2017	Mar. 13, 2017	Dec. 31, 2016	Dec. 31, 2015	Aug. 10, 2015	May 31, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.37	$ 0.56	$ 0.01	$ 0.21	$ 0.37
Preferred Stock, Par or Stated Value Per Share			0.001
Share Price			$ 0.88	$ 1	$ 1.14
Proceeds from Related Party Debt			$ 140,000	$ 200,000
Interest Expense, Total			$ 1,104,557	$ 752,948
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.75
Warrants Issued		60,000
Stock Issued During Period, Shares, Issued for Services		162,500
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Warrant Expiration Date		Mar. 8, 2020
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Warrant Expiration Date		Mar. 6, 2020
Subsequent Event [Member] | Investor [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt	$ 100,000
Interest Expense, Total	$ 6,000
Subsequent Event [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Stock Issued During Period, Shares, New Issues		700,000
Stock Issued During Period, Value, New Issues		$ 700,000
Preferred Stock, Par or Stated Value Per Share		$ 1
Conversion of Stock, Amount Issued		$ 5,000,000
Share Price		$ 2
Common Stock, Dividends, Per Share, Declared		$ 0.75